¿ Son todos los H. pylori «malos»?

Revista Espanola de Enfermedades Digestivas

Volumn 91, Issue 7, 1999, Pages 508-515

  Gisbert, Javier R ^a,b   Pajares, J M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Playa de Mojácar ^*  (Spain)

Author keywords

Eradication; Functional dyspepsia; Gastric cancer; Gastric lymphoma; Helicobacter pylori; Omeprazole; Peptic ulcer; Reflux esophagitis; Therapy

Indexed keywords

HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; REVIEW;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 0033155830     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Gisbert JP, Boixeda D, Martín de Argila C, Garcia Plaza A. Helicobacter pylori y úlcera duodenal: ¿relación causal o mera asociación? Rev Clín Esp 1997;197:693-702.
2. NIH Consensus Conference. Helicohacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
3. Malfertheiner P, Mégraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. Eur J Gastroenterol Hepatol 1997;9:1-2.
4. Gisbert JP. ¿Es el linfoma gástrico una enfermedad infecciosa? Med Clín (Barc) 1998;110:56-61.
5. Graham DY. The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 1997;350:70-1.
6. Queiroz DMM, Barbosa AJA, Mendes EN, Rocha GA, Cisalpino EO, Lima GF Jr, et al. Distribution of Campylobacter pylori and gastritis in the stomach of patients with and without duodenal ulcer. Am J Gastroenterol 1988; 83:1368-70.
7. Satoh K, Kimura K, Yoshida Y, Kasano T, Kihira K, Taniguchi Y. A topographical relationship between Helicobacter pylori and gastritis: quantitative assessment of Helicobacter pylori in the gastric mucosa. Am J Gastroenterol 1991;86:285-91.
8. Gisbert JP, Boixeda D, Álvarez Baleriola I, Redondo C, De Rafael L, Martín de Argila C, et al. Evolución de las lesiones histológicas de la mucosa gástrica tras la erradicación de Helicobacter pylori en pacientes con úlcera duodenal. Estudio inicial y a los 6 meses. Rev Esp Enferm Dig 1995; 87:281-7.
9. Axon ATR, Forman D. Helicobacter gastro-duodenitis, a serious infectious disease. Br Med J 1997;314:1430-1.
10. Moayyedi P, Axon ATR. Is there a rationale for eradication of Helicobacter pylori? Cost-benefit: the case for. Br Med Bull 1998;54:243-50.
11. Sipponen P, Varis K, Fraki O, Korri UM, Seppala K, Siurala M. Cumulative 10 yr risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. Scand J Gastroenterol 1990;25:966-73.
12. Dooley CP, Cohen H, Fitzgibbons PL. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989;321:1562-5.
13. Cullen DJE, Collins J, Christiansen KJ, Epis J, Warren JR, Cullen KJ. Long term risk of peptic ulcer disease in people with Helicobacter pylori infection: a community based study. Gastroenterology 1993;104(suppl 2):A60.
14. Nomura A, Stemmermann GN, Chyou P, Pérez-Pérez GI, Blaser MJ. Helicobacter pylori infection and the risk for duodenal ulcer and gastric ulceration. Ann Intern Med 1994;120:977-81.
15. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(suppl 2):59-69.
16. Sipponen P, Kosunen TU, Valle J, Riihelä M, Seppälä A. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 1992;45:319-23.
17. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. Br Med J 1991;302: 1302-5.
18. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-31.
19. Nomura A, Stemmermann GN, Chyou PH. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-5.
20. Correa P. Is gastric carcinoma an infectious disease? N Engl J Med 1991;325:1170-1.
21. Graham DY, Malaty HM, Go MF. Are there susceptible hosts to Helicobacter pylori infection? Scand J Gastroenterol 1994;29(suppl 205):6-11.
22. Eurogast study group. An international association between Helicobacter pylori and gastric cancer. Lancet 1993; 341:1359-62.
23. International Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori. En: Schistosomes, Liver Flukes and Helicobacter pylori. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 61. France, Lyon: International Agency for Research on Cancer; 1994. p. 177-214.
24. Forman D. Helicobacter pylori and gastric cancer. Scand J Gastroenterol 1996;31(suppl 215):48-51.
25. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40:297-301.
26. Ferguson DA, Li CH, Patel NR, Mayberry WR, Chi DS, Thomas E. Isolation of Helicobacter pylori from saliva. J Clin Microbiol 1993;31:2802-4.
27. Mapstone NP, Linch DAF, Lewis FA, Axon AT. Tompkins DS, Dixon MF, et al. Identification of H. pylori DNA in the mouths and stomachs of patients with gastritis using PCR. J Clin Pathol 1993;46:540-3.
28. Nguyen AMH, Engstrand L, Genta RM, Graham DY, El-Zaatari FAK. Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction. J Clin Microbiol 1993;31:783-7.
29. Mapstone NP, Lynch DA, Lewis FA, Axon AT, Dixon MF, Quirke P. The detection of Helicobacter pylori in faeces by the polymerase chain reaction. Ir J Med Sci 1992;161 (suppl 10):29.
30. Thomas JE, Gibson GR, Darboe MK, Dale A, Weaver LT. Isolation of Helicobacter pylori from human faeces. Lancet 1992;340:1194-5.
31. Kelly SM, Cummings JH, McFerlane GT, Grimes V, McFerlane S, Gibson GR. Occurrence of H. pylori in fecal specimens from patients with dyspepsia in the UK. Gastroenterology 1993;104:A116.
32. Blaser MJ. Not all Helicobacter pylori strains are created equal: should all be eliminated? Lancet 1997;349:1020-2.
33. Blaser MJ. Helicobacter pylori eradication and its implications for the future. Aliment Pharmacol Ther 1997;11 (suppl 1):103-7.
34. Blaser MJ. Helicobacter pylori phenotipes associated with peptic ulceration. Scand J Gastroenterol 1994;29(suppl 205):1-5.
35. Go MF, Graham DY. How does Helicobacter pylori cause duodenal ulcer disease: The bug, the host, or both? J Gastroenterol Hepatol 1994;9(suppl 1):S8-S10.
36. Blaser MJ, Chyou P, Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 1995;55: 562-5.
37. Moran AP. Pathogenic properties of H. pylori. Scand J Gastroenterol 1996;31(suppl 215):22-31.
38. Fiocca N, Guglielmetti P, Rossolini A. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol 1989;27:225-6.
39. Figura NP, Guglielmetti P, Rossolini A, et al. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcer and from patients with chronic gastritis only. J Clin Microbiol 1989;27:225-6.
40. Figura N. Identifiable Helicobacter pylori strains or factors important in the development of duodenal ulcer disease. Helicobacter 1997;2(suppl 1):S3-S8.
41. Goossens H, Glupczynski Y, Burette A, Lambert JP, Vlaes L, Butzler JP. Role of the vacuolating toxin from H. pylori in the pathogenesis of duodenal and gastric ulcer. Med Microbiol Lett 1992;1:153-9
42. Cover TL, Cao P, Lind CD, Tham KT, Blaser MJ. Correlation between vacuolating cytotoxin production by Helicobacter pylori isolates in vitro and in vivo. Infect Immun 1993;61:5008-12.
43. Xiang Z, Censini S, Bayeli PF, Telford JL, Figura N, Rappuoli R, et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995;63:94-8.
44. Crabtree JE. Immune and inflammatory responses to Helicobacter pylori infection. Scand J Gastroenterol 1996; 31(suppl 215):3-10.
45. Pan ZJ, Van der Hulst RWM, Feller M, Xiao SD, Tytgat GN, Dankert J, et al. Equally high prevalences of infection with CagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol 1997; 35:1344-7.
46. Ito Y, Azuma T, Ito S, Miyaji H, Hirai M, Yamazaki Y, et al. Analysis and typing of the VacA gene from CagA-positive strains of Helicobacter pylori isolated in Japan. J Clin Microbiol 1997;35:1710-4.
47. Yoshimura HA, Evans DG, Graham DU. DNA-DNA hybridization demonstrates apparent genetic differences between Helicobacter pylori from patients with duodenal ulcer and asymptomatic gastritis. Dig Dis Sci 1993;38: 1128-31.
48. Gisbert JP, Boixeda D, Martín de Argila C. ¿Es el cáncer gástrico una enfermedad infecciosa? Rev Esp Enferm Dig 1996;88:555-62.
49. Crabtree JE, Wyatt JI, Sobala GM, Miller G, Tompkins DS, Primrose JN, et al. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut 1993;34:1339-43.
50. Hirai M, Azuma T, Ito S, Kato T, Kohli Y, Fujiki N. High prevalence of neutralizing activity to Helicobacter pylori cytotoxin in serum of gastric carcinoma patients. Int J Cancer 1994;56:56-80.
51. Pretolani S, Figura N, Miglio F. High prevalence of serum IgG to Helicobacter pylori cytotoxin-associated protein (CagA) in a country with high gastric cancer rate: the San Marino-Study. Am J Gastroenterol 1994;89:1403.
52. Lehn N, Lwyh S, Hatz R. Serologic response to Helicobacter pylori and significance of vacuolizing cytotoxic activity of Helicobacter pylori in gastric cancer and MALT lymphoma. Am J Gastroenterol 1994;89:1394.
53. Blaser MJ, Kobayashi K, Cover TL, Cao P, Feurer IK, Pérez-Pérez GI. Helicobacter pylori infection in Japanese patients with adenocarcinoma of the stomach. Int J Cancer 1993;55:799-802.
54. Blaser MJ, Pérez-Pérez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, et al. Infection with Helicobacter pylori strains possessing CagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-5.
55. Lin JT, Wang LY, Wang JT, Want TH, Chen CJ. Ecological study of association between Helicobacter pylori infection and gastric cancer in Taiwan. Dig Dis Sci 1995;40:385-8.
56. Correa P, Fox J, Fontham E, Ruiz B, Lin YP, Zavala D, et al. Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer 1990;66:2569-74.
57. Forman D, Webb P, Parsonnet J. Helicobacter pylori and gastric cancer. Lancet 1994;343:243-4.
58. Parsonnet J. Helicobacter pylori and gastric cancer. En: Dooley, CP, Cohen, H, eds. Gastroenterol Clin North Am. Helicobacter pylori infection. Philadelphia: WB Saunders; 1993. p. 89-104.
59. Tytgat GNJ. Current indications for Helicobacter pylori eradication therapy. Scand J Gastroenterol 1996;31(suppl 215):70-3.
60. Chen M, Lee A, Hazell S, Hu P, Li Y. Immunisation against gastric infection with Helicobacter species: first step in the prophylaxis of gastric cancer? Int J Med Microbiol Virol Parasitol Infect Dis 1993;280:155-65.
61. Boixeda D, Martín de Argila C, Gisbert JP. Indicaciones para la erradicación de Helicobacter pylori. Reflexiones sobre la Conferencia de Consenso de Maastricht. Gastroenterol Hepatol 1998;21(suppl 1):29-34.
62. Gisbert JP, Boixeda D, Martín de Argila C. Infección por Helicobacter pylori: ¿dónde está el limite? Med Clin (Barc) 1997;109:802-11.
63. Martín de Argila C, Boixeda D, Gisbert JP. Cardiopatía isquémica e infección por Helicobacter pylori. En: Boixeda D, Gisbert JP, Martín de Argila C, eds. Helicobacter pylori: ¿Dónde está el limite? Barcelona: Prous Science; 1996. p. 277-87.
64. Gisbert JP, Boixeda D, Martín de Argila C. Helicobacter pylori y dispepsia no ulcerosa: una asignatura pendiente. Rev Esp Enferm Dig 1998;90:441-53.
65. Patchett SE. Helicobacter pylori eradication. Cost-benefit: the case against. Br Med Bull 1998;54:251-7.
66. Werdmuller BFM, Loffelsd RJLF. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997;42:103-5.
67. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
68. Verdú EF, Armstrong D, Idström JP, Labenz J, Stolte M, Börsch G, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 199631: 1151-6.
69. Labenz J, Tillenburg B, Peitz U, Börsch G, Idström JP, Verdú W, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92:576-81.
70. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989;64:526-30.
71. Molloy RM, Sonnenberg A. Relation between gastric cancer and previous peptic ulcer disease. Gut 1997;40:247-52.
72. Bell GD, Powell KU, Burridge SM. Experience with «triple» anti-Helicobacter pylori eradication therapy: side effects and importance of testing the pretreatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992;6:427-31.
73. Gisbert JP, Boixeda D, De Rafael L, Redondo C, Martín de Argila C, Bermejo F, et al. ¿De qué factores depende el éxito de la triple terapia «clásica» en la erradicación de Helicobacter pylori? Rev Esp Enferm Dig 1996;88:317-22.
74. Cayla R, Zerbib F, Talbi P, Mégraud F, Lamouliatte H. Pre and posttreatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure. Gut 1995;37(suppl 2):A152.
75. Cayla R, Zerbib F, Mégraud F, Lamouliatte H. Clarithromycin resistance of Helicobacter pylori strains before and after treatment: a key factor of treatment failures. Gastroenterology 1995;108:A68.
76. Gisbert JP, Boixeda D, Martín de Argila C. ¿Cuál es el papel terapéutico actual de la claritromicina en el tratamiento erradicador de Helicobacter pylori? Rev Esp Enferm Dig 1997;89:305-12.
77. López-Brea M, Domingo D, Sánchez I, Alarcón T. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. J Antimicrob Chemother 97;40:279-81.
78. Corthesy-Theulez I, Porta N, Glauser M, Saraga E, Vaney AC, Haas R, et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995;109:115-21.
79. Parsonnet J. The incidence of H. pylori infection. Aliment Pharmacol Ther 1995;9(suppl 2):45-51.